TG Therapeutics, Inc. (NASDAQ:TGTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, July 13th. The brokerage currently has a $12.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 20.00% from the stock’s current price.

According to Zacks, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. “

Several other research firms also recently weighed in on TGTX. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research report on Thursday, May 18th. Jefferies Group LLC assumed coverage on shares of TG Therapeutics in a research report on Tuesday, April 25th. They issued a “buy” rating and a $23.00 price target on the stock. Raymond James Financial, Inc. reiterated a “buy” rating on shares of TG Therapeutics in a research report on Friday, April 21st. ValuEngine upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, BidaskClub downgraded shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. TG Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $23.67.

Shares of TG Therapeutics (NASDAQ TGTX) opened at 10.00 on Thursday. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35. The stock has a 50 day moving average price of $11.07 and a 200-day moving average price of $9.79. The company’s market capitalization is $616.56 million.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/09/tg-therapeutics-inc-tgtx-upgraded-to-buy-by-zacks-investment-research-updated-updated-updated.html.

In related news, CFO Sean A. Power sold 59,976 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the transaction, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at $5,295,075.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 16.70% of the company’s stock.

Several institutional investors have recently modified their holdings of TGTX. GAM Holding AG boosted its position in shares of TG Therapeutics by 81.9% in the second quarter. GAM Holding AG now owns 98,600 shares of the biopharmaceutical company’s stock worth $991,000 after buying an additional 44,400 shares during the last quarter. Columbus Circle Investors boosted its position in shares of TG Therapeutics by 39.0% in the second quarter. Columbus Circle Investors now owns 1,396,396 shares of the biopharmaceutical company’s stock worth $14,034,000 after buying an additional 391,975 shares during the last quarter. BB&T Securities LLC boosted its position in shares of TG Therapeutics by 63.0% in the second quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 6,549 shares during the last quarter. Legal & General Group Plc boosted its position in shares of TG Therapeutics by 14.9% in the second quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,463 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of TG Therapeutics by 9.3% in the second quarter. Bank of New York Mellon Corp now owns 297,176 shares of the biopharmaceutical company’s stock worth $2,987,000 after buying an additional 25,297 shares during the last quarter. 45.68% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.